Investigation announced for Investors who lost money with shares of Inari Medical, Inc. (NASDAQ: NARI)

An investigation was announced over potential securities laws violations by Inari Medical, Inc. in connection with certain financial statements.

Investors who purchased shares of Inari Medical, Inc. (NASDAQ: NARI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether certain statements by Inari Medical, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Irvine, CA based Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. Inari Medical, Inc. reported that its annual Total Revenue rose from $383.47 million in 2022 to $493.63 million in 2023, and that its Net Loss declined from $29.26 million in 2022 to $1.63 million in 2023.

On February 28, 2024, after market hours, Inari Medical filed an Annual Report on Form 10-K with the SEC announcing "[i]n December 2023, we received a civil investigative demand ("CID") from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the "Investigation"). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals ("HCPs"). We are cooperating with the Investigation. We are unable to express a view at this time regarding the likely duration, or ultimate outcome, of the Investigation or estimate the possibility of, or amount or range of, any possible financial impact. Depending on the outcome of the Investigation, there may be a material impact on our business, results of operations, or financial condition."

Shares of Inari Medical, Inc. (NASDAQ: NARI) declined from $67.10 per share on December 19, 2023, to as low as $40.81 per share on March 05, 2023.

Those who purchased shares of Inari Medical, Inc. (NASDAQ: NARI) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.